12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Company News  |  Deals

Daiichi Sankyo, Roche deal

Roche returned rights to RG7256 to Daiichi. The BRAF inhibitor was in Phase I...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >